Table 2.

Baseline hepatic and virologic characteristics according to HCV infection status.

Variable	Total cohort N=161	HCV-infected N=25	HCV-uninfected N=136	P value*
Baseline Hepatic characteristics
Median total bilirubin (IQR)	0.5 (0.4–0.8)	0.5 (0.4–0.8)	0.6 (0.4–0.7)	.99
Median ALT (IQR)	31 (19.5–47.5)	38 (31.5–69)	29.5 (18–45)	.006
Median AST (IQR)	30 (23–49)	28 (22.5–59)	30 (23.5–47)	.86
Median albumin (IQR)	4.2 (3.9–4.4)	4.2 (3.8–4.4)	4.1 (3.9–4.4)	.78
Cirrhosis, n (%)	27 (17)	10 (40)	17 (13)	.002
Virologic characteristics
HCV genotype, n (%)
1	12/25 (48)
2	1/25 (4)
3	2/25 (8)
4	1/25 (4)
Unknown	9/25 (36)
HIV, n (%)	2 (1)	2 (8)	0 (0)	.
HBV, n (%)
HBsAg +	3 (2)	1 (4)	2 (2)	.40
HBcAb +	20 (12)	7 (28)	13 (10)	.02
HPV, n (%)	86 (53)	11 (44)	75 (55)	.78
HCV treatment received
		8 (32)
IFN+RBV		2 (25)
LDV/SOF		4 (50)
SOF + RBV		2 (25)
Timing of AVT after HCV diagnosis, median in months (IQR)		18.3 (12.6–24.8)

Abbreviations: Ab, antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AVT, antiviral treatment; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; IFN, interferon; LDV, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response.